ISDS Case Map
medicines
Bilateral investment treaties (BITs) may be a threat to access to medicines as shown by a recent legal suit by a drug multinational against Canada for invalidating a patent, writes Carlos Correa
Are the PBS and Pharmac under threat from the TPP? Certainly, the respective governments of both Australia and New Zealand think not. So why then the paranoia? Quite simply, we need the US more than they need us. In order to secure the TPP (and with it, for example, access to the lucrative US dairy market), both Australia and New Zealand will likely need to yield in several key areas.
There is a strong sense in the halls of the current TPP negotiation that the end is not in sight. And one of the primary reasons s a lack of consensus on intellectual property and pharmaceuticals issues, reports Infojustice from Lima.
Although access to medicines activists have been wise to focus our attention intently on convincing low- and middle-income countries to adopt and use all possible TRIPS-compliant flexibilities and to oppose the TRIPS-plus IP chapters in free trade agreements, we have neglected to interrogate another chapter in free trade agreements and bilateral investment treaties that perhaps pose an even greater threat to our collective access to medicines – investment chapters.
The much-hyped bilateral trade and investment agreement (BTIA) between India and the European Union (EU) would not impact the Indian generic drugs industry or lead to a change in the country's patent law, João Cravinho, EU ambassador to India, said on Friday.
A large number of people living with HIV, cancer patients and health activists took to the streets of Delhi today asking government of India not to sign a Free Trade Agreement (FTA) with the European Union (EU) as it would be detrimental to the interests of tens of thousands of people like them in the country.
We, Cambodian garment workers, sex workers, entertainment workers, people living with HIV, LGBTs, university students, feminists and human right activists from different networks and organisations came together to express our concern about the threat posed by the forthcoming EU-India free trade agreement to the lives of millions of people in Cambodia and many other developing countries across the world.
Around 2000 people including people living with HIV (PLHIV), patient groups and public health activists will take to the streets and rally from Barakhamba road to Jantar Mantar at 11.00 am on 10 April 2013 to voice concerns and protest against harmful provisions being pushed by the EU-India FTA negotiations
Will Manmohan Singh understand the clear purpose behind the national sentiment around the Supreme Court judgment on Novartis’ cancer drug Glivec? If he does, he should take a relook at the India-EU Free Trade Agreement that is cooking in his back-room.
The gains accruing to the Indian generic drugs industry as a result of the Supreme Court judgement on the Novartis case may be lost if India accepts demands by the European Union (EU) under the proposed free trade agreement (FTA) between the two sides.
